银屑病关节炎与中轴型脊柱关节炎停用TNFi后循环策略与换药策略比较:一项准实验研究
本研究在银屑病关节炎(PsA)和中轴型脊柱关节炎(axSpA)患者首次停用肿瘤坏死因子抑制剂(TNFi)后,比较作用机制循环策略(第一种TNFi换为第二种TNFi)与换药策略(第一种TNFi换为IL-17i)的3年药物留存率。PsA患者(n=406)两种策略总体无显著差异(HR 1.17,95%CI 0.87-1.58,p=0.29),但男性PsA患者换药策略停药风险显著更高;axSpA患者(n=335)换药策略总体停药风险更高(HR 1.46,95%CI 1.03-2.07,p=0.04)。两种疾病中不同策略的疾病活动度均无显著差异。
要点
- PsA患者循环与换药策略3年药物留存总体无显著差异(HR 1.17,95%CI 0.87-1.58,p=0.29)。
- axSpA患者换药策略较循环策略停药风险显著更高(HR 1.46,95%CI 1.03-2.07,p=0.04)。
- 男性PsA及因无效停用首个TNFi或影像学axSpA患者换药策略停药风险显著更高。
核心结论
- 在PsA中,循环策略与换药策略表现相似,而在axSpA中,循环策略与显著更高的药物留存率相关。
研究设计与样本
- 回顾性比较研究,纳入临床诊断为PsA(n=406)和axSpA(n=335)的患者,2019年12月本地方案由循环策略改为换药策略。
- 采用多变量Cox回归(参照组:循环组)比较3年药物留存率,并评估疾病活动度(PsA用DAS28-CRP,axSpA用BASDAI)。
主要发现
- PsA患者总体药物留存两种策略无显著差异(HR 1.17,95%CI 0.87-1.58,p=0.29),但男性PsA患者换药策略停药风险显著更高。
- axSpA患者换药策略总体停药风险更高(HR 1.46,95%CI 1.03-2.07,p=0.04)。
- 因无效停用首个TNFi的患者及影像学axSpA患者换药策略停药风险显著更高。
- PsA或axSpA中不同治疗策略的疾病活动度均无显著差异。
关键数值与推荐
- PsA总体药物留存:换药策略 vs 循环策略 HR 1.17(95%CI 0.87-1.58),p=0.29。
- axSpA总体药物留存:换药策略 vs 循环策略 HR 1.46(95%CI 1.03-2.07),p=0.04。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare a bDMARD mode of action cycle vs swap treatment strategy in patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) after first tumour necrosis factor inhibitor (TNFi) discontinuation. METHODS: In December 2019, our local treatment protocol for PsA and axSpA changed from a cycle strategy (first TNFi to second TNFi) to a swap strategy (first TNFi to IL-17i). We performed a retrospective comparison of the 3-year drug retention rate using multivariable Cox regression (ref: cycle group) and disease activity (DAS28-CRP for PsA, BASDAI for axSpA) in patients with a clinical diagnosis of PsA and axSpA. For subgroup analyses, Cox regression models were stratified by sex, reason of first TNFi discontinuation, and (non-)radiographic status in axSpA. RESULTS: In PsA patients (n=406), there was no overall significant difference in drug retention between strategies (HR: 1.17 (95% CI: 0.87 to 1.58), p=0.29), but male PsA patients had a significant higher risk for treatment discontinuation following a swap strategy. In axSpA patients (n=335), the swap strategy was overall associated with a higher risk of treatment discontinuation (HR: 1.46 (95% CI: 1.03 to 2.07), p=0.04). Patients who discontinued their first TNFi due to inefficacy and patients diagnosed with radiographic axSpA were at significant higher risk for treatment discontinuation following a swap strategy. No significant differences in disease activity were found for treatment strategies in PsA or axSpA. CONCLUSION: In PsA, the cycle and swap treatment strategy performed similarly, while in axSpA, the cycle strategy was associated with a significant higher drug retention rate.
引用
- van Es I, Vriezekolk JE, den Broeder N, et al. Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental study. RMD Open. 2025. PMID: 40562682. doi:10.1136/rmdopen-2025-005566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。